TauRx Therapeutics and University of Aberdeen Present Data on Potential Alzheimer's Drug

    By Christopher P. Singer --

In a July 29, 2008 presentation at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago, scientists involved in a collaboration between the University of Aberdeen and TauRx Therapeutics discussed data demonstrating that their candidate drug, rember, appears to slow the progress of the Alzheimer's disease.  According to a press release from the University of Aberdeen as well as TauRx's website, rember is a small molecule Tau Aggregation Inhibitor that targets the tangles (aggregates of abnormal fibres of tau protein) that form in nerve cells in the brains of Alzheimer's patients.

The data presented by the scientists indicated that patients receiving the therapeutic experienced an 81% reduction in cognitive decline over one year, and did not experience a significant decline in their mental function over the course of 19 months.  Brain imaging data performed by TauRx was said to suggest that the drug had the most significant effect in the regions of the brain thought to be critical for memory function and where the tangle density is typically high.

Dr. Claude Wischik, TauRx's Executive Chairman, and a Professor at the University of Aberdeen, characterized the Phase 2 clinical results as representing the first real hope that it may be possible to arrest progression of Alzheimer's disease.  Following up on this promising clinical data, TauRx is planning to begin a Phase 3 trial next year.  If the Phase 3 trial confirms the Phase 2 findings, the drug could be available by 2012.

Comments

[DAMIEN]

je suis personnelement tres interessé par cette nouvelle mollecule et ce nouveau traitement.Ma mère est actuellement atteinte de cette maladie.Si il y avait une possibilité de lui faire suivre la phase '3 'de test basée sur le volontaria ,elle serait d'accord.
Merci d'avance pou elle de vos réponses et de vos commentaires.

[jill goldberg]

How does one become part of the phase three trial

[Ana Zadicoff]

I'm very interested in contact with Dr Wischik because my husband suffer a cognitive disease that grow very fast.
Please, answer ASAP. We can travel to any place of the word if you consider a mininimun possibility for him. I can provide all the history of my husband under your request

[Chris Singer]

Dear Damien, Jill, and Ana:

We do not have any details regarding the enrollment in the upcoming clinical trials that TauRx is planning to launch. I would suggest starting by contacting TauRx directly. TauRx's website seems to still be in the early stages of development, but it should at least provide you with a place to start your search.

My family has also had the unfortunate situation of dealing with Alzheimer's disease. It is a particularly cruel disease, so hopefully this therapeutic represents a real step forward in treatment. Good luck in your efforts to enroll in the trial.

[nikola sorak]

Where can I obtain Rember medication?
My wife is in the later stages of Alzheimers desease.

[Terence]

TauRx has not been given approval for phase 3 studies. It may be in 2009 or even 2010 if the FDA delays it.
Hopefully, it may be approved for phase 3 earlier in Europe by the EMEA. Best to place a google alert for it. Good luck!

[Lakehal]

Hello,
My name is jawad, my family has the ofortunate situation of dealing with Alzeimer disease too. Few days ago we heard about the new medication the "rember" and also about a trial in 2009 or 2010 if the FDA delays it. Our questions are 1) when the medication will be on the market if the FDA delays it 2)About the trial: How and when can we put our Family name on the list trial for participate on the next phase.

[Ronni Adam]

My mother is in the early stages of alzhimer's and would benefit from this new drug how can she go on the waiting list for stage three trial. Please respond if you can help.